Drug
Amiselimod clinical trials
Also written MT-1303.
- studies test it
- 12
- open now
- 0
- in phase 3
- 0
- first study started
- 2012
How studies write it
Studies that test it under each name
Development codes
Studies by the year they started
11 studies that test it; most in 2013 (3)
| Year | Studies |
|---|---|
| 2012 | 1 |
| 2013 | 3 |
| 2014 | 3 |
| 2015 | 3 |
| 2021 | 1 |
By phase
A phase 1/2 study counts in both.
- Phase 1
- 6
- Phase 2
- 6
What it is tested for
Each study’s main condition, where its own words name it.
Who runs them
Industry 12 · Other 0
Mitsubishi Tanabe Pharma Corporation (11) · Bausch Health Americas, Inc. (1)
Studies
Open first, then newest update. How each study uses amiselimod is read from its arms, and is right about nine times in ten.
Testing it · 12
- Study Evaluating Efficacy and Safety of Amiselimod (MT-1303) in Mild to Moderate Ulcerative ColitisCompletedPhase 2Bausch Health Americas, Inc.NCT04857112Written as Low Dose MT-1303
- Extension Study of MT-1303 in Subjects With Crohn's DiseaseCompletedPhase 2Mitsubishi Tanabe Pharma CorporationNCT02389790Written as MT-1303
- Exploratory Study of MT-1303 in Systemic Lupus Erythematosus PatientsCompletedPhase 1Mitsubishi Tanabe Pharma CorporationNCT02307643Written as MT-1303 Low dose
- Safety and Efficacy of MT-1303 in Subjects With Moderate to Severe Active Crohn's DiseaseCompletedPhase 2Mitsubishi Tanabe Pharma CorporationNCT02378688Written as MT-1303
- Dose-finding Study of MT-1303CompletedPhase 2Mitsubishi Tanabe Pharma CorporationNCT01742052Written as MT-1303-Low
- Extension Study of MT-1303CompletedPhase 2Mitsubishi Tanabe Pharma CorporationNCT01890655Written as MT-1303-Low
- Mass Balance Study of MT-1303CompletedPhase 1Mitsubishi Tanabe Pharma CorporationNCT02293967Written as MT-1303
- Comparative Oral Bioavailability Study of MT-1303CompletedPhase 1Mitsubishi Tanabe Pharma CorporationNCT02310048Written as MT-1303-FormA
- A Phase 1 Study to Explore the Cardiac Pharmacodynamics of MT-1303CompletedPhase 1Mitsubishi Tanabe Pharma CorporationNCT02193217Written as MT-1303-Low
- Dose-finding Study of MT-1303 in Subjects With Moderate to Severe Chronic Plaque PsoriasisCompletedPhase 2Mitsubishi Tanabe Pharma CorporationNCT01987843Written as MT-1303-Low
- Pharmacokinetics (PK), Pharmacodynamics (PD) and Safety Study of MT-1303 in Subjects With Crohn's DiseaseCompletedPhase 1Mitsubishi Tanabe Pharma CorporationNCT02148185Written as MT-1303
- Safety, Tolerability, Pharmacokinetics and Pharmacodynamics Study of MT-1303 in Subjects With Inflammatory Bowel DiseaseCompletedPhase 1Mitsubishi Tanabe Pharma CorporationNCT01666327Written as MT-1303
Codes
What other systems call amiselimod · ClinicalTrials.gg INT000818
- UNII (FDA) 358M5150LYAMISELIMODConfirmed FDA, Wikidata
- Wikidata Q27256444amiselimodConfirmed FDA, Wikidata
- NCI Thesaurus C166641AmiselimodOne source FDA
- DrugBank DB17074One source Wikidata
| System | Code | Name there | Checked by |
|---|---|---|---|
| UNII (FDA) | 358M5150LY | AMISELIMOD | Confirmed FDA, Wikidata |
| Wikidata | Q27256444 | amiselimod | Confirmed FDA, Wikidata |
| NCI Thesaurus | C166641 | Amiselimod | One source FDA |
| DrugBank | DB17074 | — | One source Wikidata |
Also registered as amiselimod hydrochloride (UNII AY898D6RU1).
“Confirmed” means two independent publishers link the code to this drug; “one source”, one does and its name agrees.